Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
12/2/2014Meridian Life Science Awarded SBIR II by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine
CINCINNATI--(BUSINESS WIRE)--Dec. 2, 2014-- Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce they have been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding for this activity will be provided through a Small Business Innovation Research (SBIR) contract. Process development... 
 Printer Friendly Version
11/6/2014Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 6, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported fourth quarter and full-year fiscal 2014 net revenues of $46.7 million and $188.8 million, respectively, a decrease of 5% and an increase of less than 1%, respectively, from the same periods of the prior fiscal year; reporte... 
 Printer Friendly Version
9/3/2014Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae
CINCINNATI--(BUSINESS WIRE)--Sep. 3, 2014-- Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene® molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. diffic... 
 Printer Friendly Version
9/2/2014Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2015 and Reaffirms Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Sep. 2, 2014-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2015 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2015, management expects net revenues to be in the range of $193 to $200 million, or 2% to 5% growth, and per share diluted ... 
 Printer Friendly Version
8/6/2014Meridian Bioscience and the University of Tennessee Research Foundation Enter into a License Agreement for Electrokinetic Sensor Technology
CINCINNATI--(BUSINESS WIRE)--Aug. 6, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO), today announced that it has entered into a technology and commercial license agreement with the University of Tennessee Research Foundation (UTRF) for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes. ... 
 Printer Friendly Version
7/24/2014Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 24, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported fiscal 2014 third quarter and first nine months net sales of $47.2 million and $142.1 million, respectively, flat and an increase of 2%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income of $13.1 million, a decrease of 16% from the same period of the prior fisca... 
 Printer Friendly Version
5/28/2014Meridian Bioscience Receives Canadian Licenses for illumigene® Mycoplasma and illumigene® Pertussis
CINCINNATI--(BUSINESS WIRE)--May 28, 2014-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene® molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing so... 
 Printer Friendly Version
4/24/2014Meridian Bioscience Reports Second Quarter 2014 Operating Results and Revises Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Apr. 24, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported record fiscal 2014 second quarter and first six months net sales of $50.1 million and $94.9 million, respectively, increases of 6% and 2%, respectively, from the same periods of the prior fiscal year; reported second quarte... 
 Printer Friendly Version
3/27/2014Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® Pertussis
CINCINNATI--(BUSINESS WIRE)--Mar. 27, 2014-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Bordetella pertussis (B. pertussis), its fifth assay on the illumigene platform. This innovative test is the first FDA-cleared molecular stand-alone assay for B. pertussis providing a solution to the unmet need of today’s healthcare market. ... 
 Printer Friendly Version
2/18/2014Bioline Launches New Products for Epigenetics Research
CINCINNATI--(BUSINESS WIRE)--Feb. 18, 2014-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), announces that it has entered the rapidly growing Epigenetics field, with the launch of the first kits in the new EPIK™ product range; EPIK™ Fast Quantification Kit and EPIK™ Amplification Kit. These EPIKTM Kits have been developed to meet the needs of researchers employing PCR and real-time PCR analy... 
 Printer Friendly Version
2/7/2014Bioline Launches High Performance SensiFAST™ cDNA Synthesis Kit
CINCINNATI--(BUSINESS WIRE)--Feb. 7, 2014-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the SensiFASTTM cDNA synthesis kit. Powered by a newly developed Reverse Transcriptase enzyme with enhanced properties and in combination with the unique TransAmp™ buffer; SensiFASTTM cDNA synthesis kit is the choice for scientists who need consistent, unbiased, fi... 
 Printer Friendly Version
1/22/2014Meridian Bioscience Reports First Quarter 2014 Operating Results, Declares Increased Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported first quarter net sales of $44.8 million, a decrease of 1% from the same period of the prior fiscal year; reported first quarter operating income of $11.6 million, a decrease of 11% from the same period of the prior fiscal year; reported first quarter net earnings of $7.4 million, or $0.18 per ... 
 Printer Friendly Version
1/15/2014Meridian Bioscience Provides Preliminary First Quarter Operating Results, Reaffirms Guidance for Fiscal 2014 and Comments on the Business
CINCINNATI--(BUSINESS WIRE)--Jan. 15, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced weaker than expected preliminary operating results for the first quarter ended December 31, 2013. Fiscal 2014 First Quarter Preliminary Outlook Due to factors including reduced hospital admissions and declining C. difficile incidence rates in hospitals putting further pressure on an already competitive market, Life Science shipment... 
 Printer Friendly Version
1/14/2014Bioline Expands into Singapore
CINCINNATI--(BUSINESS WIRE)--Jan. 14, 2014-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the opening of an office in Singapore to support and grow the Bioline business in Singapore and in Asia. With the opening of the new office; Bioline will provide direct sales, technical support, and training to its existing customers and can also offer a same-day delivery to many ... 
 Printer Friendly Version
1/10/2014Meridian Bioscience Granted Special 510(k) Clearance for TRU FLU® to Add Avian H7N9 Influenza A Virus Analytical Sensitivity Claim
CINCINNATI--(BUSINESS WIRE)--Jan. 10, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the company’s TRU FLU® assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU® is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens. New strains of Influenza viruses are continuously emerging to ... 
 Printer Friendly Version